Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F20%3A00079666" target="_blank" >RIV/00023001:_____/20:00079666 - isvavai.cz</a>
Alternative codes found
RIV/00023884:_____/20:00008690
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S0002870320300272?token=E3F4B98F08F79A262F987A4873934BB2591489F5D4393005DFB4FAAD1E7898B363F7A6CC0C2A94846B21DE47A68DEA16" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0002870320300272?token=E3F4B98F08F79A262F987A4873934BB2591489F5D4393005DFB4FAAD1E7898B363F7A6CC0C2A94846B21DE47A68DEA16</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ahj.2020.01.012" target="_blank" >10.1016/j.ahj.2020.01.012</a>
Alternative languages
Result language
angličtina
Original language name
Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial
Original language description
Background: Adverse cardiac remodeling is a major risk factor for the development of post myocardial infarction (MI) heart failure (HF). This study investigates the effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute ST-segment-elevation myocardial infarction (STEMI). Methods: In this double-blind, randomized, placebo-controlled trial patients with first STEMI were eligible. To preferentially enrich patients at high risk of adverse remodeling, main inclusion criteria were a left-ventricular ejection fraction (LVEF) ≤45% and an infarct size >10% on day 5 to 9 post MI as measured by cardiac MRI. Patients were then randomized to 6 months treatment with either 25 mg fulacimstat (n = 54) or placebo (n = 53) twice daily on top of standard of care starting day 6 to 12 post MI. The changes in LVEF, LV end-diastolic volume index (LVEDVI), and LV end-systolic volume index (LVESVI) from baseline to 6 months were analyzed by a central blinded cardiac MRI core laboratory. Results: Fulacimstat was safe and well tolerated and achieved mean total trough concentrations that were approximately tenfold higher than those predicted to be required for minimal therapeutic activity. Comparable changes in LVEF (fulacimstat: 3.5% ± 5.4%, placebo: 4.0% ± 5.0%, P = .69), LVEDVI (fulacimstat: 7.3 ± 13.3 mL/m2, placebo: 5.1 ± 18.9 mL/m2, P = .54), and LVESVI (fulacimstat: 2.3 ± 11.2 mL/m2, placebo: 0.6 ± 14.8 mL/m2, P = .56) were observed in both treatment arms. Conclusion: Fulacimstat was safe and well tolerated in patients with left-ventricular dysfunction (LVD) after first STEMI but had no effect on cardiac remodeling. © 2020 Elsevier Inc.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American heart journal
ISSN
0002-8703
e-ISSN
—
Volume of the periodical
224
Issue of the periodical within the volume
June 2020
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
129-137
UT code for WoS article
000540371700015
EID of the result in the Scopus database
2-s2.0-85084081354